

## Fareston<sup>®</sup> (toremifene) – New warnings

- On May 12, 2017, the FDA approved updates to the *Warnings and Precautions* section of the <u>Fareston (toremifene)</u> drug label, regarding hepatotoxicity and risk of uterine malignancy.
- Fareston is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.
- Hepatotoxicity, both increases in the serum concentration for grade 3 and 4 transaminitis and hyperbilirubinemia, including jaundice, hepatitis, and non-alcoholic fatty liver disease, have also been reported in clinical trials and postmarketing with Fareston.
  - Liver function tests should be performed periodically.
- Endometrial cancer, endometrial hypertrophy, hyperplasia, and uterine polyps have been reported in some patients treated with Fareston. Endometrial hyperplasia of the uterus was observed in animals treated with Fareston. Long-term use of Fareston has not been established in patients with pre-existing endometrial hyperplasia.
  - All patients should have baseline and annual gynecological examinations. In particular, patients at high risk of endometrial cancer should be closely monitored.
- Fareston carries a boxed warning for QT prolongation.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.